Literature DB >> 27582254

SCARB2/LIMP2 deficiency in action myoclonus-renal failure syndrome.

Leanne Dibbens1, Michael Schwake2, Paul Saftig3, Guido Rubboli4.   

Abstract

Action myoclonus-renal failure syndrome (AMRF) is an autosomal recessive progressive myoclonus epilepsy (PME) associated with renal dysfunction that appears in the second or third decade of life and that is caused by loss-of-function mutations in the SCARB2 gene encoding lysosomal integral membrane protein type 2 (LIMP2). Recent reports have documented cases with PME associated with SCARB2 mutations without renal compromise. Additional neurological features can be demyelinating peripheral neuropathy, hearing loss and dementia. The course of the disease in relentlessly progressive. In this paper we provide an updated overview of the clinical and genetic features of SCARB2-related PME and on the functions of the LIMP2 protein.

Entities:  

Keywords:  LIMP2; SCARB2; cerebellar syndrome; lysosome; myoclonus; photosensitivity; progressive myoclonus epilepsy

Mesh:

Substances:

Year:  2016        PMID: 27582254     DOI: 10.1684/epd.2016.0843

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  7 in total

Review 1.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

2.  A novel homozygous splice-site mutation in SCARB2 is associated with progressive myoclonic epilepsy with renal failure.

Authors:  Abolfazl Yari; Reza Molla Ali-Nejad; Nasrollah Saleh-Gohari
Journal:  Neurol Sci       Date:  2021-03-26       Impact factor: 3.307

Review 3.  Gaucher disease: Basic and translational science needs for more complete therapy and management.

Authors:  Gregory A Grabowski; Armand H M Antommaria; Edwin H Kolodny; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-12-29       Impact factor: 4.797

4.  The Deficiency of SCARB2/LIMP-2 Impairs Metabolism via Disrupted mTORC1-Dependent Mitochondrial OXPHOS.

Authors:  Yujie Zou; Jingwen Pei; Yushu Wang; Qin Chen; Minli Sun; Lulu Kang; Xuyuan Zhang; Liguo Zhang; Xiang Gao; Zhaoyu Lin
Journal:  Int J Mol Sci       Date:  2022-08-03       Impact factor: 6.208

5.  Genetic and phenotypic spectrum of Chinese patients with epilepsy and photosensitivity.

Authors:  Yue Niu; Pan Gong; Xianru Jiao; Zhao Xu; Yuehua Zhang; Zhixian Yang
Journal:  Front Neurol       Date:  2022-08-02       Impact factor: 4.086

6.  A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies.

Authors:  Tobias Baumgartner; Mar Carreño; Rodrigo Rocamora; Francesca Bisulli; Antonella Boni; Milan Brázdil; Ondrej Horak; Dana Craiu; Cristina Pereira; Renzo Guerrini; Victoria San Antonio-Arce; Andreas Schulze-Bonhage; Sameer M Zuberi; Tove Hallböök; Reetta Kalviainen; Lieven Lagae; Sylvie Nguyen; Sofia Quintas; Ana Franco; J Helen Cross; Matthew Walker; Alexis Arzimanoglou; Sylvain Rheims; Tiziana Granata; Laura Canafoglia; Cecilie Johannessen Landmark; Arjune Sen; Rohini Rattihalli; Rima Nabbout; Elena Tartara; Manuela Santos; Rui Rangel; Pavel Krsek; Petr Marusic; Nicola Specchio; Kees P J Braun; Patricia Smeyers; Vicente Villanueva; Katarzyna Kotulska; Rainer Surges
Journal:  Epilepsia Open       Date:  2021-01-13

7.  Miglustat Therapy for SCARB2-Associated Action Myoclonus-Renal Failure Syndrome.

Authors:  Imran H Quraishi; Anna M Szekely; Anushree C Shirali; Pramod K Mistry; Lawrence J Hirsch
Journal:  Neurol Genet       Date:  2021-07-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.